Embarking on the CAR-T Journey
Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.
In this exclusive PC Podcast interview, Renier Brentjens, MD, PhD, deputy director and chair of medicine at the Roswell Park Comprehensive Cancer Center, discusses:
- How he has seen the field evolve since its inception, and what excites him most about its future
- How the Roswell Park expansion helps improve patient access to CAR T-cell therapy
- The key safety concerns associated with CAR T-cell therapy, along with how Roswell Park aims to mitigate potential risks
- How Roswell Park is working to make CAR T-cell therapy more widely available
- The steps needed to be taken at the regulatory and healthcare policy levels in order to support the broader adoption of CAR T-cell therapy
The latest episode of The Pharmaceutical Commerce Podcast is available directly on Audioboom, Spotify, or iHeart.
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
New UK Consortium Obtains $1.34M Grant to Launch Automated Cell Therapy Manufacturing Platform
July 15th 2025Cellular Origins, CGT Catapult, and Resolution Therapeutics partner up to design a fully automated, scalable CGT manufacturing solution, with the goal of accelerating patient access to cell therapies.
Multi-Indication Drug Branding in Today’s Pharmaceutical Industry
July 2nd 2025As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.
